Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up.
Aliment Pharmacol Ther
; 25(7): 849-55, 2007 Apr 01.
Article
em En
| MEDLINE
| ID: mdl-17373924
ABSTRACT
BACKGROUND:
Patients undergoing dialysis usually have a poor response to conventional hepatitis B vaccination.AIM:
To observe the effects of intradermal hepatitis B (HB) vaccination in a 13-month prospective study of adult patients with end-stage renal failure. The patients were with or without previous hepatitis B vaccination, but all had antibody titres <10 mUI/mL.METHODS:
Patients were allotted to two groups previous hepatitis B virus vaccination and no previous hepatitis B virus vaccination or anti-HBs titres <10 mUI/mL. Patients in both groups received 16 i.d. injections of 0.1 mL of hepatitis B virus vaccine over an eight-week period. Patients had antibody titres assessed before vaccination, 1 month after and every 3 months for a year. Antibody titres >/=10 mUI/mL were considered protective.RESULTS:
Seventy patients completed the protocol. Protective titres were elicited in 82% of each group. Age, time under dialysis, diabetes, smoking and body-mass index were not associated with seroconversion. Persistent protective titres >12 months occurred in 27 (58.7%). Adverse events were trivial.CONCLUSION:
Intradermal hepatitis B virus vaccination is an alternative in end-stage renal failure.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra Hepatite B
/
Hepatite B
/
Falência Renal Crônica
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Aliment Pharmacol Ther
Assunto da revista:
FARMACOLOGIA
/
GASTROENTEROLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Brasil